{"title":"肝门周围胆管癌中拷贝中性的杂合性缺失模式的发现具有潜在的预后价值。","authors":"Sutheemon Techa-Ay, Sasithorn Watcharadetwittaya, Raksawan Deenonpoe, Kitti Intuyod, Anchalee Techasen, Poramate Klanrit, Watcharin Loilome, Prakasit Sa-Ngiamwibool, Malinee Thanee","doi":"10.21873/anticanres.17734","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>Perihilar cholangiocarcinoma (pCCA) is an aggressive bile duct cancer with a poor prognosis (10-40% 5-year survival after resection), that is mostly found in Thailand and has limited prognostic models. Copy neutral loss of heterozygosity (cnLOH) in various cancers affects their progression leading to poorer overall survival. This study aimed to explore cnLOH patterns in individual pCCA patients in order to develop a predictive model for prognostic biomarkers.</p><p><strong>Materials and methods: </strong>DNA was extracted from 14 frozen tissues and chromosome microarray (CMA) was performed to analyze cnLOH.</p><p><strong>Results: </strong>Analysis of cnLOH revealed a median of 14 events per sample. The most frequent cnLOH was observed on chromosome 1q, followed by high occurrences on chromosomes 2, 3p, 5q, 6q, 7q, 11q, and 12q. Importantly, we identified several specific cnLOH regions (2p23.2, 2p23.3, and 6p11.1) where alterations were significantly associated with decreased overall survival (<i>p</i><0.05).</p><p><strong>Conclusion: </strong>These results provide evidence that cnLOH events may contribute to disease progression and influence overall survival in patients with pCCA, indicating a potential role in the underlying molecular mechanisms of this malignancy.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 9","pages":"3737-3748"},"PeriodicalIF":1.7000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Discovery of a Copy-neutral Loss of Heterozygosity Pattern in Perihilar Cholangiocarcinoma With Potential Prognostic Value.\",\"authors\":\"Sutheemon Techa-Ay, Sasithorn Watcharadetwittaya, Raksawan Deenonpoe, Kitti Intuyod, Anchalee Techasen, Poramate Klanrit, Watcharin Loilome, Prakasit Sa-Ngiamwibool, Malinee Thanee\",\"doi\":\"10.21873/anticanres.17734\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background/aim: </strong>Perihilar cholangiocarcinoma (pCCA) is an aggressive bile duct cancer with a poor prognosis (10-40% 5-year survival after resection), that is mostly found in Thailand and has limited prognostic models. Copy neutral loss of heterozygosity (cnLOH) in various cancers affects their progression leading to poorer overall survival. This study aimed to explore cnLOH patterns in individual pCCA patients in order to develop a predictive model for prognostic biomarkers.</p><p><strong>Materials and methods: </strong>DNA was extracted from 14 frozen tissues and chromosome microarray (CMA) was performed to analyze cnLOH.</p><p><strong>Results: </strong>Analysis of cnLOH revealed a median of 14 events per sample. The most frequent cnLOH was observed on chromosome 1q, followed by high occurrences on chromosomes 2, 3p, 5q, 6q, 7q, 11q, and 12q. Importantly, we identified several specific cnLOH regions (2p23.2, 2p23.3, and 6p11.1) where alterations were significantly associated with decreased overall survival (<i>p</i><0.05).</p><p><strong>Conclusion: </strong>These results provide evidence that cnLOH events may contribute to disease progression and influence overall survival in patients with pCCA, indicating a potential role in the underlying molecular mechanisms of this malignancy.</p>\",\"PeriodicalId\":8072,\"journal\":{\"name\":\"Anticancer research\",\"volume\":\"45 9\",\"pages\":\"3737-3748\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Anticancer research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21873/anticanres.17734\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17734","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
Discovery of a Copy-neutral Loss of Heterozygosity Pattern in Perihilar Cholangiocarcinoma With Potential Prognostic Value.
Background/aim: Perihilar cholangiocarcinoma (pCCA) is an aggressive bile duct cancer with a poor prognosis (10-40% 5-year survival after resection), that is mostly found in Thailand and has limited prognostic models. Copy neutral loss of heterozygosity (cnLOH) in various cancers affects their progression leading to poorer overall survival. This study aimed to explore cnLOH patterns in individual pCCA patients in order to develop a predictive model for prognostic biomarkers.
Materials and methods: DNA was extracted from 14 frozen tissues and chromosome microarray (CMA) was performed to analyze cnLOH.
Results: Analysis of cnLOH revealed a median of 14 events per sample. The most frequent cnLOH was observed on chromosome 1q, followed by high occurrences on chromosomes 2, 3p, 5q, 6q, 7q, 11q, and 12q. Importantly, we identified several specific cnLOH regions (2p23.2, 2p23.3, and 6p11.1) where alterations were significantly associated with decreased overall survival (p<0.05).
Conclusion: These results provide evidence that cnLOH events may contribute to disease progression and influence overall survival in patients with pCCA, indicating a potential role in the underlying molecular mechanisms of this malignancy.
期刊介绍:
ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed.
ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies).
Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.